Gate Bioscience Inc. has disclosed protein transport protein Sec61 complex inhibitors reported to be useful for the treatment of cancer, viral infections, malaria, prion infection, light chain amyloidosis, autoimmune diseases and renal and urinary system genetic disorders.

Neurocrine Biosciences Inc. has described new muscarinic M4 receptor antagonists reported to be useful for the treatment of tremor, dystonia and parkinsonism.

Beigene Co. Ltd. has divulged proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase binding moiety covalently linked to a mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1)-targeting moiety reported to be useful for the treatment of cancer.

Grey Wolf Therapeutics Ltd. has identified phenyl-sulfamoyl-benzoic acid derivatives acting as endoplasmic reticulum aminopeptidase 1 (ERAP1) inhibitors reported to be useful for the treatment of cancer, viral infection, inflammatory and immunological disorders.

Hebei Feinisi Biotechnology Co. Ltd. has synthesized shared epitope-containing HLA DR molecule (SE-DR) affinity peptides reported to be useful for the treatment of rheumatic diseases.

Novartis AG has disclosed 3C-like proteinase (3CLpro; Mpro; nsp5) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection.

Shanghai Aryl Pharmtech Co. Ltd. and Zhejiang Hisun Pharmaceutical Co. Ltd. have described pyrimidocyclic derivatives acting as son of sevenless homolog 1 (SOS1) inhibitors reported to be useful for the treatment of cancer, cardiofaciocutaneous and Noonan syndrome.

Theranocure Co. Ltd. has divulged gadolinium complexes targeting β-amyloid protein acting as magnetic resonance imaging (MRI) contrast agents reported to be useful for the diagnosis of Alzheimer's disease and the treatment of Parkinson's and Alzheimer's disease.